BACKGROUND: Heart failure (HF) is a state of inappropriately sustained inflammation, suggesting the loss of normal immunosuppressive mechanisms. Regulatory T-lymphocytes (Tregs) are considered key suppressors of immune responses; however, their role in HF is unknown. We hypothesized that Tregs are dysfunctional in ischemic cardiomyopathy and HF, and they promote immune activation and left ventricular (LV) remodeling.
METHODS:
Adult male wild-type C57BL/6 mice, Foxp3-diphtheria toxin receptor transgenic mice, and tumor necrosis factor (TNF) α receptor-1 (TNFR1) −/− mice underwent nonreperfused myocardial infarction to induce HF or sham operation. LV remodeling was assessed by echocardiography as well as histological and molecular phenotyping. Alterations in Treg profile and function were examined by flow cytometry, immunostaining, and in vitro cell assays.
RESULTS:
Compared with wild-type sham mice, CD4 +
Foxp3
+ Tregs in wildtype HF mice robustly expanded in the heart, circulation, spleen, and lymph nodes in a phasic manner after myocardial infarction, beyond the early phase of wound healing, and exhibited proinflammatory T helper 1-type features with interferon-γ, TNFα, and TNFR1 expression, loss of immunomodulatory capacity, heightened proliferation, and potentiated antiangiogenic and profibrotic properties. Selective Treg ablation in Foxp3-diphtheria toxin receptor mice with ischemic cardiomyopathy reversed LV remodeling and dysfunction, alleviating hypertrophy and fibrosis, while suppressing circulating CD4 + T cells and systemic inflammation and enhancing tissue neovascularization. Tregs reconstituted after ablation exhibited restoration of immunosuppressive capacity and normalized TNFR1 expression. Treg dysfunction was also tightly coupled to Treg-endothelial cell contact-and TNFR1-dependent inhibition of angiogenesis and the mobilization and tissue infiltration of CD34 +
Flk1
+ circulating angiogenic cells in a C-C chemokine ligand 5/C-C chemokine receptor 5-dependent manner. Anti-CD25-mediated Treg depletion in wild-type mice imparted similar benefits on LV remodeling, circulating angiogenic cells, and tissue neovascularization.
CONCLUSIONS:
Proinflammatory and antiangiogenic Tregs play an essential pathogenetic role in chronic ischemic HF to promote immune activation and pathological LV remodeling. The restoration of normal Treg function may be a viable approach to therapeutic immunomodulation in this disease.
M
yocardial infarction (MI) triggers a heightened inflammatory response, followed by inflammation resolution and wound healing. 1 Ideally, this results in tissue repair and preservation of cardiac function. However, if the infarct is large enough or the healing response is insufficient, adverse left ventricular (LV) remodeling and heart failure (HF) develop over time, accompanied by chronic and inappropriately sustained inflammation. 2 In addition to increased levels of proinflammatory cytokines, recent studies have indicated that in chronic ischemic HF, there is robust expansion of both innate (eg, macrophages and dendritic cells [DCs] ) [3] [4] [5] and adaptive (eg, T cells) 6 immune cells in the heart that are pathologically activated, induce tissue injury, and contribute to adverse remodeling. Hence, ischemic cardiomyopathy can be considered a state of chronic immune system activation.
Persistent immune activation in HF suggests insufficiency of normal immunomodulatory mechanisms. In this regard, regulatory T cells (Tregs) are viewed as key orchestrators of immune homeostasis and peripheral tolerance. 7 Suppression of effector T cell (Teff) responses by Tregs may occur via multiple pathways, including the secretion of inhibitory cytokines such as interleukin (IL)-10 and transforming growth factor (TGF)-β, granzyme Aand perforin-mediated Teff cytolysis, Teff metabolic disruption, and contact-dependent suppression of DC−Teff interactions. 7 Lack of the Treg-specific transcription factor forkhead box protein-3 (Foxp3) has been linked to severe autoimmune disease in both humans 8 and rodents. 9 After acute MI, Treg activation is beneficial; it limits inflammation and modulates macrophage phenotype, thereby improving cardiac wound healing and remodeling. 10, 11 We have recently demonstrated that CD4 + T-cells, including Tregs, are globally expanded and activated in chronic murine ischemic cardiomyopathy. 6 Why there is persistent Teff activation and inflammation despite Treg expansion in ischemic HF is unclear, but it may result from defective Treg-mediated immunosuppression. It is notable that in autoimmune arthritis, the inflammatory microenvironment alters the phenotype of peripherally induced Tregs to a proinflammatory state that accelerates synovial damage, 12 suggesting that Treg plasticity may underlie self-injury. Treg expansion in ischemic cardiomyopathy may also potentially exacerbate HF via nonimmune mechanisms. Specifically, Tregs are antiangiogenic and induce endothelial cell (EC) apoptosis 13, 14 and secrete TGF-β, which promotes extracellular matrix accumulation. 15 In the failing heart, these effects would promote capillary rarefaction and interstitial fibrosis that exacerbate adverse LV remodeling. However, whether Treg dysfunction occurs in chronic HF and the role that Tregs play in disease pathogenesis are unknown. Hence, we tested the hypothesis that Tregs become dysfunctional, proinflammatory, and tissue-injurious in chronic ischemic HF, and that this phenotypic switch contributes to sustained inflammation and the progression of LV remodeling.
METHODS
The data and analytic methods pertinent to the findings of this study are available from the corresponding author on reasonable request.
Mouse Models and In Vivo Protocols
All animal studies were approved by the Institutional Animal Care and Use Committee of the University of Alabama at Birmingham and were compliant with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (DHHS publication No. 85-23, revised 1996) . A total of 225 mice were used. C57BL/6 wild-type (WT) and TNFα receptor (TNFR) 1 −/− mice were obtained from Jackson Laboratories (stock #000664 and #002818, respectively) and Foxp3-diphtheria toxin receptor (DTR) mice from Dr Alexander Rudensky (Memorial Sloan Kettering Cancer Center). After general anesthesia and mechanical ventilation, male mice 8 to 10 weeks of age underwent either sham surgery or left coronary artery ligation to induce large MI and ischemic HF as previously described. 
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Based on pilot studies, Treg ablation in Foxp3-DTR mice was induced by intraperitoneal diphtheria toxin (DT; 20 μg/kg/d) at 28 and 29 days after ligation or sham surgery and again at 38 and 39 days with a dose of 10 μg/kg/d (vehicle control). In some studies, DT administration was accompanied by coadministration of the small molecule CCR5 antagonist maraviroc, 10 mg/kg (PBSvehicle control) intraperitoneal daily from 28 to 56 days after MI. 19 For antibody-mediated Treg ablation, C57BL/6 mice received anti-CD25 (or immunoglobulin [IgG] control) (100 μg/mouse) initiated on day 28 after MI and repeated every 10 days thereafter for a total of 3 doses. We ensured that HF mice exhibited comparable LV remodeling by echocardiography 25 to 27 days after MI before randomization to the respective treatment groups.
Echocardiography
M-mode and 2-dimensional echocardiography were performed under 1% to 2% inhaled isoflurane anesthesia (with 100% supplemental O 2 ) and continuous ECG monitoring using a VisualSonics Vevo770 High-Resolution System and 30 MHz RMV707B scanhead. 6, 20, 21 A heated, bench-mounted adjustable rail system was used, with body temperature maintained at 37.0°C±0.5°C and heart rate 500±50 bpm. Imaging was performed in the parasternal long-axis and short-axis views. LV chamber volume in end-diastole (EDV) and end-systole (ESV) was determined using the area-length method from parasternal long-axis images captured in ECG-gated Kilohertz Visualization mode. LV ejection fraction was used to index systolic function and calculated as [(EDV−ESV)/EDV]*100.
Immune Cell Isolation and Flow Cytometry
Live mononuclear cells were isolated from the peripheral blood, heart, spleen, and lymph nodes (LNs) and processed for flow cytometry as previously described. 3, 5, 6, 20, 21 All cells were fixed with 1% paraformaldehyde for flow cytometric analysis. Cells were initially stained for membrane markers by incubating with antibodies against CD3-FITC (BD Biosciences), CD4-Qdot 650NC/eVolve 605/PE/Cy7 (eBioscience), and TNFR1 (Santa Cruz Biotechnology, rabbit polyclonal sc7895) for 1 hour. Anti-TNFR1 was then conjugated with secondary goat anti-rabbit antibody attached to Alexa Fluor 405 for 30 minutes. Cells were then permeabilized with 0.5% Tween-20 for 20 minutes, followed by intracellular staining with anti-Foxp3-APC, TNFα-PE, interferon (IFN) γ-eFluor 450, interleukin (IL)-4-PerCP-eFluor 710, and IL-17-Alexa Fluor 700 (eBioscience) for 45 to 60 minutes. All staining was performed on ice to maintain cell morphology. Flow cytometric data were acquired using a BD FACSdiva LSR-II flow cytometer and analyzed using FlowJo software v10.0.6. In select studies, we evaluated the intravascular cell contribution to the cardiac cell isolate. One day after MI, BV605-conjugated anti-CD45 antibody (3 µg/mouse; Biolegend) was given intravenously, and 3 minutes later, hearts were harvested and mononuclear cells were isolated either before or after modified Langendorff retrograde coronary perfusion with PBS for 5 minutes. The cell isolate was stained with PE/Cy7-conjugated anti-CD45 antibody, and the frequency of BV605-CD45 + cells among total PE/Cy7-CD45 + cells was measured by flow cytometry.
Cytokine Analysis
Peripheral blood was coagulated on ice and centrifuged at 3000 g to separate serum. Mouse cytokine bead array for T helper (Th) 1/Th2/Th17 cytokine analysis (BD Biosciences) was used as per the manufacturer's protocol with results presented as mean fluorescence intensity (MFI).
Gene Expression Analysis
Total messenger RNA from the LV remote zone (≈10 mg) or sorted cells was extracted using Trizol reagent, and gene expression was measured as described previously. 3, 5, 6, 16, 17 Table  I in the online-only Data Supplement lists the forward and reverse primer sequences used.
Histological Analysis
Fibrosis and capillary density were measured using Masson's Trichrome and isolectin IB4 staining, respectively, as previously described. 3, 6, 16, 18 Fibrosis was quantified in the LV border zone in an automated fashion using Metamorph software v6.3r5 (Molecular Devices). Collagen (blue) staining threshold was initially adjusted so that all fibrotic areas were captured, and tissue fibrosis was then determined from 4 to 6 high-power fields per section, expressed as percent of total cross-sectional area. Myocyte membranes were stained using Alexa Fluor (AF) 555-conjugated wheat-germ agglutinin (Invitrogen). Myocyte apoptosis was evaluated using the DeadEnd Fluorometric TUNEL System (Promega). 3, 18 For cardiac Treg quantitation, LV sections were embedded in optimal cutting temperature compound (Tissue-Tek) and then kept at −80°C. In addition, 4 µm LV sections were fixed with ice cold acetone, rehydrated in PBS, and stained with antimouse CD4 (1:50, GK1.5 cat#14-0041082, secondary antirat AF555, 1:100) and FoxP3 (1:50, 5H10L18 cat#700914, secondary anti-rabbit AF488, 1:100). Nuclei were stained with DAPI. CD4
+

Foxp3
+ cells were counted in 5 high-power fields (60x) per LV region (remote, border, and infarct zone). Images were acquired using a Nikon A1 confocal microscope.
BrdU Pulse Studies
To assess Treg proliferation in vivo, BrdU (2 mg/mouse intraperitoneal) was injected 2 to 3 hours before euthanasia. After euthanasia, cells were harvested and fixed for flow cytometric analysis of BrdU + Tregs, labeled with anti-BrdU-eFluor 450 (eBioscience).
In Vitro Tube Formation Assay
Matrigel (50 μL) was layered in 96-well plates and incubated at 37°C for 30 minutes, followed by plating of mouse coronary ECs (MCECs), 50 000 cells/well in supplemented endothelial basal media. Splenic CD4 + T cells were isolated from naïve Foxp3-DTR mice (pretreated with intraperitoneal thioglycollate 2.5 mL, 5 days before harvest), Foxp3-DTR HF mice, and TNFR1 −/− HF mice by negative selection using the Miltenyi CD4 + T-cell isolation kit. 
Statistical Analysis
All data are mean±SD. Group variances were compared using the Brown−Forsythe test, whereas normality was assessed using the D'Agostino-Pearson test. For statistical comparisons of 2 groups, 2-tailed paired t test or unpaired t test with equal or unequal variance was used. For comparison of >2 groups, 1-or 2-way ANOVA with either Tukey's or Bonferroni posttest was used. The specific approaches applied are stated in the figure legends. All analyses were done using GraphPad Prism version 7.0a. A P<0.05 was considered significant.
RESULTS
Mice Exhibit Ischemic Cardiomyopathy and Chronic HF After Coronary Ligation
Mice reliably demonstrated signs of ischemic cardiomyopathy and chronic HF 8 weeks after nonreperfused MI. 3, 6 Compared with sham-operated mice, HF mice exhibited marked LV dilatation (increased EDV and ESV) and depressed LV ejection fraction by echocardiography ( Figure  IA in the online-only Data Supplement), and greater heart, LV, lung, and spleen weight by gravimetry ( Figure IB Figure 1A . Tregs were recruited to the heart in ≤1 day after MI (≈4-fold increase) in ligated hearts versus sham hearts and increased dramatically by 3 days (≈57-fold).
Tregs remained elevated ≈3-fold at 7 days, normalized by 2 weeks, and subsequently reexpanded in chronic HF (8 weeks after MI) to levels ≈7-fold over sham. By comparison, naïve hearts contained a small tissue-resident Treg population. At 8 weeks after MI, the failing heart also exhibited increased gene expression of several chemokines, chemokine receptors, and adhesion molecules that drive Treg recruitment and activation, [22] [23] [24] [25] [26] [27] including CCL22, CXCL5, CXCL10, CXCL13, CX3CL1, CCR7, VCAM-1, and ICAM-1 (and strong trends toward increased CCL19 and CCL21) ( Figure III in the online-only Data Supplement). In blood, both Treg frequency (percent CD4 + T cells) and absolute levels were comparable between sham and MI mice at 1 week after MI (Figure 1B) . However, at later time points, circulating Treg frequency was increased in HF mice, with absolute levels augmented ≈2-fold over sham at 8 weeks after MI.
To define the contribution of circulating Tregs to the measured cardiac Treg population, we performed intravascular CD45 labeling in vivo immediately before cardiac harvest, with or without subsequent ex vivo retrograde coronary perfusion, in mice 24 hours after MI. As shown in Figure IV in the online-only Data Supplement, even under these conditions of high tissue inflammation, intravascular leukocytes comprised <5% of the total cardiac mononuclear cell population, and isolation purity was similar between perfused and nonperfused hearts. Moreover, cardiac CD4 and Foxp3 immunostaining revealed a ≈4-to 7-fold increase in CD4 +
Foxp3
+ cells in the remote, border, and infarct (scar) zones of failing hearts as compared with sham ( Figure 1C ), confirming the flow cytometry results indicative of tissue Treg expansion in HF.
In HF, a pathological cardiosplenic axis contributes to LV remodeling. 3 Therefore, we assessed Treg abundance in the spleen-and heart-draining mediastinal LNs in chronic HF (8 weeks after MI). As shown in Figure 1D , both Treg frequency and number in the spleen and LNs were significantly increased in HF mice versus sham. Circulating Treg populations are dynamic and characterized by a balance between proliferation and apoptosis; Treg survival is linked to the availability of IL-2 28 and Treg plasticity to IL-6. 12 To evaluate Treg proliferation, we administered BrdU to mice 2 to 3 hours before tissue collection. Absolute numbers of BrdU + proliferating Tregs were increased in the heart, blood, spleen, and LNs of HF mice versus sham (Figure V in the online-only Data Supplement ), with increased frequency (% total Tregs) in the heart, blood, and spleen ( Figure 1E ). Moreover, cardiac Tregs in failing hearts exhibited considerably higher proliferative rates than the overall CD45 + cardiac cell population (Figure V in the online-only Data Supplement ), and Tregs in sham-operated hearts in turn exhibited greater proliferative rates than Tregs in lymphoid organs and blood. This was accompanied by significantly increased IL-2 expression in the spleen, IL-6 expression in the spleen and heart, and serum levels of IL-6 in HF ( Figure 1F ).
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HF Tregs Exhibit Proinflammatory Features and Diminished Immunomodulatory Capacity
Under suitable conditions, Foxp3 + Tregs are capable of expressing Th1, Th2, and Th17 cytokines and exhibiting plasticity toward a proinflammatory phenotype. 12, 29 Accordingly, we measured intracellular TNFα, IFNγ, IL-4, and IL-17 levels in Tregs by flow cytometry. As shown in Figure 2A , whereas circulating TNFα + Treg frequency was comparable between sham and HF mice early (1 week) after MI, at 4 weeks after MI and beyond, blood TNFα + Tregs were robustly increased in HF mice. TNFα + Treg frequency was also significantly increased in the heart and spleen, together with a nearly 6-fold increase in total TNFα + Tregs in heart-draining LNs in HF ( Figure TNFα exerts divergent effects on cardiac remodeling after MI that are directly referable to its cell surface receptors, TNFR1 and TNFR2. 16 Whereas TNFR1 exerts proinflammatory and prohypertrophic effects, TNFR2 is protective and counterbalances these detrimental responses. TNFα also has divergent receptor-dependent 30 On the other hand, in inflamed synovial tissues, TNFα promotes Treg dysfunction by inducing protein phosphatase-1-mediated Foxp3 dephosphorylation via NF-κB, 31 a transcription factor primarily activated by TNFR1 in HF. 16 Therefore, we next investigated whether Treg TNFR expression was altered during the progression of HF.
Tregs preferentially express TNFR2, which is necessary for proper Treg immunosuppressive function. 32, 33 Consistent with prior studies, Tregs in both HF and sham mice robustly expressed TNFR2 + (generally >98% of circulating CD4 + Foxp3 + cells) up to 8 weeks after MI (Figure VIE in the online-only Data Supplement). TNFR1-deficient Tregs are strongly immunosuppressive. 34 However, presumably because of low lymphocytic TNFR1 expression, prior studies have failed to detect TNFR1 on Tregs using fluorochrome-conjugated antibodies. 32, 33 To improve flow cytometric TNFR1 detection, we used a primary rabbit antimouse TNFR1 antibody 16 and a secondary Alexa-fluor 405-conjugated goat anti-rabbit antibody. We stained splenocytes from HF mice for CD4, Foxp3, TNFα, TNFR1, and nuclei with DAPI, and we visualized stained cells using imaging flow cytometry (ImageStream). As shown in Figure 2B, + Tregs were significantly increased in infarcted hearts by 1 day after MI, peaking at 3 days, normalized by 2 weeks, and then reexpanded in chronic HF (8 weeks after MI) to ≈6-fold higher levels over sham ( Figure 2C ). This was accompanied by changes in the frequency of TNFR1 + Tregs in the heart. In naïve hearts, ≈60% of the total Treg population expressed TNFR1; this initially decreased significantly to ≈20% at 1 day after MI, normalized by 3 days after MI, and increased at 8 weeks to ≈90% of cardiac 
Periodic Treg Depletion in HF Reverses LV Remodeling
We next performed DT-induced Treg depletion 9 in Foxp3-DTR sham and HF mice as illustrated in Figure  VIIIA in the online-only Data Supplement. In pilot experiments, 20 µg/kg DT intraperitoneal resulted in ≈60% Treg depletion by 2 days with complete reconstitution by ≈7 to 10 days (Figure VIIIB in the online-only Data Supplement). At 25 days after MI, HF mice with comparable LV remodeling by echocardiography ( Figure VIIIC in the online-only Data Supplement) were randomized to receive either DT or PBS over 4 weeks (sham mice similarly treated). As shown in Figure 3A and 3B, pathology, short-axis histological sections, and gravimetry revealed cardiac and LV enlargement in PBS-treated HF mice that was substantially less in DT-treated HF mice. Echocardiography revealed significant LV dilatation (increased EDV and ESV) and dysfunction (decreased EF) in HF-PBS mice as compared with sham ( Figure VIIIC in the onlineonly Data Supplement) that progressed over the 4-week treatment period ( Figure 3C and 3D, Figure VIIID in the online-only Data Supplement). In contrast, HF-DT mice, with similar degrees of LV remodeling at 4 weeks after MI, exhibited improvements in EDV, ESV, and EF (indicative of reverse remodeling) to levels significantly better than HF-PBS mice ( Figure 3C and3D, Figure VIIID in the online-only Data Supplement). Heart rate was comparable among all treatment groups. Periodic Treg depletion also reduced circulating levels of several proinflammatory (IL-17, IL-2, and IL-6) and profibrotic (IL-6 and IL-4) cytokines in HF mice ( Figure Figure 3D ). These controls established that modulation of LV remodeling in Foxp3-DTR HF mice was specifically related to dysfunctional Treg depletion and the HF state rather than nonspecific effects related to DT or induced immune cell death.
Periodic Treg Depletion in HF Reduces Cardiac Fibrosis and Improves Neovascularization
As shown in Figure 4A , cardiac peri-infarct zone interstitial fibrosis (trichrome staining) in HF-PBS mice was markedly increased versus sham-PBS mice. Although there were no changes in fibrosis in sham-DT hearts, DT treatment significantly reduced fibrosis in failing hearts. Moreover, remote zone LV gene expression revealed a marked increase in collagen I and collagen III messenger RNA in HF-PBS hearts versus sham, with loss of this upregulation in HF-DT hearts ( Figure 4B ). To evaluate myocardial neovascularization, we performed isolectin IB4 and wheat-germ agglutinin staining. HF-PBS mice displayed a reduced myocardial capillary/myocyte ratio ( Figure 5A ), increased myocyte cross-sectional area (Figure 5A) , and decreased overall capillary number ( Figure  X in the online-only Data Supplement) versus sham mice treated with either PBS or DT (which were comparable). It is important to note that Treg depletion in HF-DT mice normalized both the capillary/myocyte ratio and capillary number to levels observed in sham hearts, and also reduced myocyte size, indicating enhanced neovascularization and alleviation of pathological hypertrophy.
We next evaluated the effects of Treg depletion on CD34 + Flk1 + circulating angiogenic cells (CACs), 35 which are thought to contribute to functional neovascularization. 35, 36 As shown in Figure 5B , blood CACs Figure 5C ) similarly revealed a ≈2-to 3-fold increase in CD34 + Flk1 + cell frequency in HF-DT hearts compared with HF-PBS hearts, without changes in sham hearts. It is interesting to note that DT treatment also increased CACs in the spleen and mediastinal LNs (which were decreased at baseline in HF) in both sham and HF mice versus their respective PBS treated counterparts, without differences in the bone marrow of any group. Further assessment of absolute CAC number in HF-PBS and HF-DT mice confirmed that periodic Treg depletion expanded CAC populations in the blood, failing heart, and spleen, with a trend toward a CAC increase in mediastinal LNs ( Figure 5D ). Moreover, DT administration in WT animals did not change blood CACs from baseline in sham mice and failed to increase CACs in HF mice ( Figure XI in the online-only Data Supplement), excluding a nonspecific effect of DT on CACs.
C-C chemokine ligand 5 (CCL5) signaling via C-C chemokine receptor 5 (CCR5) plays an essential role in the tissue recruitment of CACs. 37 As shown in Figure 5E , cardiac CCL5 gene expression (remote zone) was increased nearly 11-fold and CCR5 expression nearly 3-fold in HF-DT mice compared with HF-PBS mice and sham-PBS mice. Cardiac CCL5 expression was also significantly increased in sham mice treated with DT. To define the role of CCR5 in CAC responses, Foxp3-DTR HF mice with comparable LV remodeling after MI were randomized and treated with the small molecule CCR5 antagonist maraviroc (10 mg/kg) or PBS-vehicle daily during DT administration ( Figure XIIA and XIIB in the online-only Data 
Tregs Reconstituted After Treg Depletion in HF Regain Immunomodulatory Capacity
Circulating HF Tregs at 8 weeks after MI reconstituted after periodic Treg ablation ( Figure 6A ) displayed decreased TNFR1 expression without change in TNFR2 expression ( Figure 6B ). Circulating total CD4 + T cells (but not CD8 + T cells) decreased after Treg depletion, suggesting reestablishment of Teff suppression and reduced systemic inflammation ( Figure 6C ). Indeed, in vitro Teff proliferation assays revealed restoration of immunosuppressive capacity in reconstituted splenic Tregs, which significantly inhibited Teff proliferation compared with untreated HF splenic Tregs ( Figure 6D ). Although reconstituted Tregs had less TNFR1 expression, dysfunctional immunomodulation was not specifically related to TNFR1 because splenic Tregs from TNFR1 −/− mice with HF (8 weeks after MI) also failed to suppress Teff proliferation, analogous to wild-type HF Tregs (Figure 6D) . Notably, TNFR1 −/− HF Teff cells exhibited similar basal proliferation rates (52.9±3.7%) as WT HF Teffs (49.8±24.8%), indicating that TNFR1 loss in Teffs did not directly impact their proliferative capacity. This finding suggested that alternate mechanisms underlie the loss of Treg immunosuppression. In this regard, a recent elegant study 38 demonstrated that inflammatory signals (via Toll-like receptors) metabolically reprogram Tregs toward glycolysis via upregulation of the glucose transporter Glut1, and that Glut1 expression is sufficient to both augment Treg proliferation and diminish Treg suppressive function. As shown in Figure XIII in the online-only Data Supplement, circulating Glut1 hi Tregs were significantly increased in HF mice versus sham mice. Hence, in addition to proinflammatory features, HF Tregs exhibit metabolic features associated with proliferation and reduced immunomodulatory capacity. Although TNFR1 expression is a specific biomarker for Treg dysfunction, it appears not to be required for the development of immunosuppressive alterations.
Antibody-Mediated Treg Depletion in HF Alleviates LV Remodeling
To complement studies of genetically mediated Treg depletion and explore a potentially translatable therapeutic approach, we performed Treg depletion studies using anti-CD25 antibody. 11 Although Tregs classically express CD25, effector T cells may also upregulate Figure 7C ). Anti-CD25 also increased CAC frequency and absolute levels in blood at 5 and 8 weeks after MI and in the heart and spleen at 8 weeks after MI ( Figure 7D ). We also observed a significant increase in CAC numbers at 8 weeks after MI in bone marrow after anti-CD25 treatment (Figure 7D) . Additionally, compared with IgG-treated HF mice, anti-CD25 HF mice exhibited decreased cardiac expression of the proinflammatory mediators IFNγ, IL- 
Flk1
+ CACs and quantitation of circulating levels at 1 and 4 weeks after initiating DT or PBS as per the protocol in Figure VIIIA in the online-only Data Supplement (ie, 5 and 8 weeks after MI or sham operation). C, Frequency of CD34 + Flk1 + CACs in the heart, spleen, LN, and bone marrow (BM) in the same groups at 8 weeks. D, Absolute CAC counts in blood (5 and 8 weeks after MI), and heart, spleen, LN, and BM of Foxp3-DTR HF mice given DT or PBS at 8 weeks after MI. E, LV gene expression (remote zone) of CCR5 and CCL5 in sham and HF Foxp3-DTR mice treated with either DT or PBS. Statistical comparisons: A through C and E, 2-way ANOVA (Bonferroni posttest); D, 2-tailed unpaired t test. N=5 to 9/group. *P<0.05; **P<0.01; ***P<0.001. CAC indicates circulating angiogenic cell; CCL5, C-C chemokine ligand 5; CCR5, C-C chemokine receptor 5; DTR, diphtheria toxin receptor; HF, heart failure; LN, lymph node; LV, left ventricular; MI, myocardial infarction; and WGA, wheat-germ agglutinin.
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17, and TNFR1 and the profibrotic factors IL-10 and IL-4 ( Figure XIVF in the online-only Data Supplement). TGFβ and connective tissue growth factor gene expression was similar between the HF groups. Hence, unlike the acute MI period, 10, 11 antibody-mediated Treg depletion in ischemic cardiomyopathy ameliorated pathological LV remodeling and inflammation.
HF Tregs Exert Augmented TNFR1-and Cell Contact-Dependent Antiangiogenic Effects
Given that Tregs modulate neovascularization in failing hearts, we directly evaluated antiangiogenic effects of Tregs using MCEC tube formation assays. Mouse splenic CD4 + T cells were isolated using the Miltenyi CD4 isolation kit, and CD4 (Figure 8B ), but when cultured together, tube formation was not attenuated, suggesting Treg-mediated suppression of the antiangiogenic effects of Teffs. In contrast, HF CD4 + Teffs had no effect on tube formation, whereas HF Tregs profoundly inhibited angiogenesis (>2-fold versus naïve Tregs) and also tended to inhibit (rather than improve) tube formation in the presence of Teffs. Studies using Transwell inserts established that T-cell-mediated antiangiogenic effects required cell-to-cell contact with MCECs, whereas Tregmediated suppression of the antiangiogenic effects of Teffs did not and was a paracrine rather than juxtacrine effect ( Figure −/− HF Treg coculture significantly increased MCEC expression of VEGFa, VEGFb, VEGFR1, and CCL5. Moreover, annexin V staining revealed <1% frequency of annexin V + apoptotic MCECs, indicating that Treg-mediated angiogenic effects resulted from changes in the MCEC transcriptome rather than induction of MCEC apoptotic cell death. Taken together, these data indicate that in addition to the modulation of CACs, dysfunctional Tregs in HF exert robust antiangiogenic effects that require both Treg-EC contact and TNFR1 signaling.
DISCUSSION
In this study, we demonstrate several novel findings. First, in ischemic cardiomyopathy, there is global expansion and proliferation of broadly dysfunctional Tregs that express proinflammatory Th1 cytokines and TNFR1 and have diminished immunomodulatory capabilities, increased Glut1 expression, and potentiated antiangiogenic and profibrotic properties. Tregs expand and −/− HF mice. All cells were isolated 8 weeks after MI, and the data for HF Foxp3-DTR mice are the same as in Figure 2D . Each experiment was conducted 3 to 4 times in triplicate using cells isolated from 3 to 4 mice. ORIGINAL RESEARCH ARTICLE change their phenotype in a phasic manner after MI, beyond the early phase of wound healing that accompanies the long-term progression of HF. Moreover, the failing heart is a favorable chemokine milieu for T-cell recruitment and expansion. Second, dysfunctional Tregs are essential for adverse cardiac remodeling because selective Treg ablation in ischemic cardiomyopathy reversed LV remodeling and dysfunction, alleviating hypertrophy, fibrosis, and systemic inflammation while enhancing tissue neovascularization. As indicated by the Treg ablation studies, the pathological Treg phenotype is not fixed but rather dynamic and reversible; Tregs reconstituted after depletion exhibited restoration of immunosuppressive capacity and normalized TNFR1 expression. Third, Treg dysfunction is tightly linked to neovascularization in the failing heart via both cell contact-and TNFR1-dependent antiangiogenic effects, potentially related to modulated expression of proangiogenic mediators, and the mobilization and tissue infiltration of CACs, in part related to CCL5/CCR5 signaling. The results suggest that the direct effects of heart-localized Tregs on cardiac ECs contribute to capillary rarefaction in HF. Taken together, these findings establish an essential role for dysfunctional Tregs in the pathogenesis of chronic ischemic HF and suggest that restoration of Treg function may be a fruitful approach to therapeutic immunomodulation. Prior work has established a beneficial role for Tregs in cardiac remodeling early after MI. 11, 40, 41 Here we assessed the in vivo role of Tregs in chronic ischemic HF. Unlike the acute MI period, when the phasic activation and resolution of tissue inflammation are required for wound healing, ischemic cardiomyopathy is a state of inappropriately sustained inflammation that is tissueinjurious. 2 Prior work has shown that chronic inflam- 
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mation in HF is characterized by augmentation of both innate and adaptive immune responses, [1] [2] [3] [4] [5] [6] with local and systemic expansion of macrophages, DCs, and CD4 + effector and memory T cells, and the elaboration of several proinflammatory protein mediators that have detrimental effects on the failing heart.
Broad immune activation in HF suggests compromise of intrinsic immunoregulatory networks. Tregs comprise an important immunomodulatory T-cell subset that expresses the transcription factor Foxp3 9 and constitutes 5% to 10% of circulating CD4 + T cells. 29 They may be thymus-derived (natural Tregs) or peripherally induced from naïve CD4 + T cells (induced Tregs) in response to specific microenvironmental cues. 42 Because Treg loss-offunction results in chronic autoimmune disease, 9 these cells play a critical role in immunosuppression that theoretically should impart beneficial effects in proinflammatory states such as HF. Indeed, the adoptive transfer of normally functioning Tregs ameliorates adverse remodeling induced by angiotensin II 43 and acute nonreperfused MI in mice. 10, 11, 41 Nonetheless, how endogenous Tregs respond to persistent inflammation in chronic HF after MI and their role in LV remodeling is completely unknown.
Our studies establish for the first time that Tregs reexpand in chronic HF after MI. However, unlike in the acute MI period, they are dysfunctional without immunosuppressive capacity and induce cardiac pathology. Moreover, Tregs exhibit heightened proliferation, suggesting that in addition to peripheral conversion in lymphoid tissues and subsequent tissue recruitment, local renewal contributes importantly to cardiac Treg expansion. It is interesting to note that, compared with Tregs in blood and lymphoid tissue, Tregs in the heart exhibit greater proliferative rates even in the absence of cardiac injury, implicating local renewal as particularly important for Treg persistence in the heart. Tregs are considered to achieve immunosuppression and peripheral tolerance primarily through inhibitory effects on effector T-cell function, 7 either directly via inhibitory cytokine secretion, cytolysis, and metabolic disruption or indirectly by inhibition of DC function. As we have previously shown, because there is heightened systemic expansion of DCs and CD4 + and CD8 + T cells in ischemic cardiomyopathy, 3, 6 progressive Treg dysfunction may represent a central mechanism for dysregulated innate and adaptive immune activation. Normalization of Treg immunosuppressive function after circumscribed Treg depletion was accompanied by reduced circulating levels of CD4 + but not CD8 + T cells, suggesting that in ischemic HF, CD4 + T-cell populations are more closely regulated by Tregs and, by extension, DCs.
Tregs are classically considered stable in their functional behavior and phenotype. 31 Emerging evidence indicates, however, that Tregs are dynamic, with an orchestrated balance between cell division and apoptosis, as well as phenotypic modulation in different tissue niches. 28 IL-2 is a key homeostatic regulator that suppresses Treg apoptosis while enhancing Treg proliferation. 28 Inflammatory cytokines such as IL-6 promote Treg plasticity and antagonize immunosuppressive function, 12, 31 whereas TNFα, in the presence of IL-2, boosts Treg proliferation via TNFR2 signaling. 30 Because HF is characterized by increased levels of several proinflammatory cytokines, including TNFα, IL-6, and IL-2, 2 findings also consistent with our current and prior studies, 3, 6, 17 it follows that the microenvironment in the failing heart would be conducive to both Treg expansion and phenotypic instability. Beyond proinflammatory cytokines, we have shown local upregulation of chemokines, chemokine receptors, and adhesion molecules that promote Treg trafficking, recruitment, and activation in HF (including CCL22, CXCL5, CXCL10, CXCL13, CX3CL1, CCR7, VCAM-1, and ICAM-1), [22] [23] [24] [25] [26] [27] as well as augmented Treg Glut1 expression, which ORIGINAL RESEARCH ARTICLE promotes glycolytic reprogramming, proliferation, and immunomodulatory dysfunction. 38 Hence, multiple factors likely provide a platform for Treg dysfunction in HF.
Defective suppressive function of circulating Tregs has also been reported in a small study of human HF, 44 consistent with our results. However, that study also reported reduced Treg frequency, diverging from our observation of Treg expansion in murine ischemic HF. The reasons for this divergence are unclear but may be related to several factors, including heterogeneity of the study population (which included subjects both with and without prior MI), the impact of comorbidities (eg, hypertension, diabetes mellitus) on Tregs, and differences in HF disease stage. It is important to note that absolute blood Treg number in humans was not quantified. Hence, further studies are needed to resolve the Treg profile associated with human HF.
Increased cellular TNFα, IFNγ, and TNFR1 expression accompanied the loss of Treg immunosuppressive function in chronic HF, consistent with a proinflammatory Treg transition. Although TNFα can increase proliferation and activation of mouse Tregs via TNFR2, 30 it can also induce the opposite effects via TNFR1 in mice with type I diabetes mellitus and via canonical NF-κB signaling in human Tregs. 31, 45 In ischemic HF, NF-κB is predominantly activated by TNFR1, which, in contrast to TNFR2, exacerbates pathological LV remodeling. 16, 17 Because HF Tregs exhibited increased TNFR1 and TNFα expression without changes in TNFR2, augmented TNFR1 signaling and greater intracellular crosstalk between TNFR1 and TNFR2 46 likely contribute to Treg dysfunction. Our studies with TNFR1-deficient HF Tregs established this to be the case but with a primary impact of TNFR1 on Treg inhibition of angiogenesis rather than Treg immunosuppressive function.
Modulation of angiogenesis by Tregs is context-specific. The tumor microenvironment recruits Tregs that promote immune tolerance and angiogenesis. 47 In contrast, after vascular ischemic injury, Tregs robustly inhibit neovascularization by suppressing proangiogenic macrophages and CD3 + T cells. 14 Moreover, via direct cell contact, Tregs inhibit EC angiogenesis and tube formation in vitro. 13 Here we show that HF Tregs exhibit potent direct antiangiogenic effects mediated by cell contact with cardiac ECs (as would occur in failing myocardium) and TNFR1 (which is upregulated in HF Tregs). Dysfunctional Tregs also appear to suppress the mobilization of CACs. In this regard, chronic HF is characterized by reduced numbers of CACs, 48 a phenomenon thought to contribute to deficient endothelial repair and neovascularization and shown to predict long-term cardiovascular mortality. 49 We have shown, to our knowledge for the first time, that circulating CACs, diminished in HF, are vigorously expanded on the pulsed ablation and functional restoration of Tregs, with repletion of splenic and lymphoid reservoirs, increased CAC mobilization, and augmented CAC recruitment to the heart. Hence, the improvement of myocardial neovascularization after Treg depletion in HF likely reflects the combined effects of both diminished direct inhibitory Treg-EC intrinsic interactions and cardiac CAC expansion. The mechanisms linking Tregs to CAC recruitment were dependent, at least in part, on modulation of the CCR5/CCL5 axis, previously shown to be critical for CAC mobilization and trafficking during wound healing. 37 A key finding of our study is that periodic genetic Treg depletion in ischemic cardiomyopathy reverses both pathological LV remodeling and the altered immunomodulatory Treg phenotype. At the chamber level, selective Treg ablation resulted in smaller LV volume, less pathological hypertrophy, and improved systolic function; in human HF, these are important surrogate markers for improved clinical outcomes. Moreover, Treg depletion resulted in improved myocardial capillary density as discussed earlier and a significant reduction in collagen I and collagen III expression and interstitial fibrosis, which has been independently linked to mortality risk in humans. 50 This may reflect in part the suppression of circulating CD4 + T cells, as we have shown cardiac profibrotic effects of splenic CD4 + T cells from mice with HF in vivo after adoptive transfer. 6 The benefits of Treg depletion appeared to be independent of effects on cardiomyocyte apoptosis in the failing heart. Notably, we previously demonstrated that HF macrophages directly depress cardiomyocyte contractility on cell-to-cell contact. 5 This raises the possibility that Tregs may exert analogous effects, although this idea was not specifically examined. Alleviation of cardiac remodeling in chronic HF was also achieved with anti-CD25-mediated Treg depletion, suggesting a possible approach to clinical translation.
Periodic Treg depletion normalized Treg immunosuppressive function and diminished circulating Teffs and systemic inflammation. This finding suggests that the immune system can endogenously recalibrate in chronic HF, and that circumscribed targeting of dysfunctional immune cell subsets may be an effective anti-inflammatory strategy. Presumably, ablation of pathological Tregs triggered the induction of new Treg populations with intact function and antigenic tolerance that then suppressed ongoing injurious Teff responses to ultimately repair remodeled myocardium. These results are diametrically opposite to the observed detrimental effects of Treg depletion on wound healing and remodeling in the acute MI period, 11 highlighting important differences in immune cell activation and inflammatory profiles during the acute and chronic phases of remodeling after MI.
CONCLUSIONS
In summary, ischemic cardiomyopathy in mice is characterized by diffuse expansion and proliferation of Tregs with proinflammatory features, deficient immunosuppressive capacity, and heightened antiangiogenic ORIGINAL RESEARCH ARTICLE effects. Dysfunctional Tregs are required for adverse LV remodeling at the tissue and chamber levels, with prominent pathological effects on hypertrophy, fibrosis, and tissue neovascularization, the last related to both TNFR1-dependent direct effects on ECs and Tregmediated regulation, in part through CCL5/CCR5, of CAC mobilization and recruitment. The immunocompromised Treg phenotype in HF exhibits plasticity and normalizes on selective depletion and subsequent reconstitution with new Tregs. These findings identify dysfunctional Tregs as an appealing therapeutic target for the resolution of chronic inflammation in ischemic cardiomyopathy and HF.
